Focused On-demand Library for Synaptosomal-associated protein 25

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.







Alternative names:

Super protein; Synaptosomal-associated 25 kDa protein

Alternative UPACC:

P60880; B2RAU4; D3DW16; D3DW17; P13795; P36974; P70557; P70558; Q53EM2; Q5U0B5; Q8IXK3; Q96FM2; Q9BR45


Synaptosomal-associated protein 25 (SNAP-25), also known as Super protein and Synaptosomal-associated 25 kDa protein, plays a pivotal role in the regulation of neurotransmitter release. It is involved in the molecular mechanisms of vesicle docking and membrane fusion, essential for synaptic function in neuronal systems. SNAP-25's interaction with CENPF influences plasma membrane recycling, and it modulates the gating characteristics of the KCNB1 potassium channel in pancreatic beta cells.

Therapeutic significance:

The association of SNAP-25 with congenital myasthenic syndrome 18, characterized by muscle weakness and developmental delays, underscores its clinical relevance. Understanding the role of SNAP-25 could open doors to potential therapeutic strategies for treating neuromuscular transmission disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.